【摘要】 目的:探讨房颤转复前持续时间对胺碘酮预防房颤复发疗效的影响。方法:选择房颤病例共84例(男50例,女34例),根据转复前房颤持续时间分为2组。A组:持续时间小于48h;B组:持续时间大于48h。选用静脉点滴或口服胺碘酮来转复房颤,预防复发的方法为先用负荷剂量400mg/d,共14d,然后为维持剂量50～200mg/d,可根据患者的疗效以及副作用在此范围内调整剂量。分别于房颤转复后1月、3月、6月以及12月观察两组的房颤复发率以及胺碘酮的安全性。结果:A组患者服用胺碘酮后1月、3月、6月以及12月房颤复发率分别为0%、11%、23%、32%;B组患者分别为1%、15%、20%、41%,统计学分析显示两组间无显著性差异(P<0.05)。结论:转复前房颤持续时间对胺碘酮预防房颤复发无明显影响。更多还原

【Abstract】 Objective:To assess the influence of the duration before cardioversion on preventing the recurrence of atrial fibrillation with amiodarone. Methods: 84 patients with atrial fibrillation were examined in this study . According to the duration before cardioversion ,they were divided into two groups ,A group: the duration before cardioversion is less than 48h; B group: the duration before cardioversion is more than 48h. After cardioversion with amiodarone or recovered to sinus rhythm spontaneously , amiodarone (50～200 mg/d) was administered to the patients of two groups, the recurrence rate was compared between the two groups after the administration of amiodarone at 1 month, 3 months, 6 months and 12 months, respectively. The side effect of amiodarone was also observed. Results: the recurrence rate after using amiodarone for 1 month, 3 months, 6 months and 12 months was 0%、11%、23%、32% respectively in group A, and 1%、15%、20%、41% in group B. Statistical analysis showed that there are no significant difference between the two groups (P<0.05). Conclusion: There are no significant influence of the duration before cardioversion on preventing the recurrence of atrial fibrillation with amiodarone.更多还原